Table 1.
Characteristics of the study group
| Patients | N = 86 | |
|---|---|---|
| Sex | n | % |
| Male | 55 | 64 |
| Female | 31 | 36 |
| Type of HSCT | n | % |
| MUD | 59 | 69 |
| HLA ID SIB | 18 | 21 |
| HLA MM REL | 9 | 10 |
| Source of stem cells | n | % |
| Peripheral blood | 71 | 83 |
| – after T cell depletion in vitro | 8 | 9 |
| Bone marrow | 15 | 17 |
| Diagnosis | n | % |
| Malignant (M) | 64 | 74 |
| Acute lymphoblastic leukaemia (ALL) | 33 | 38 |
| Acute myeloblastic leukaemia (AML) | 17 | 20 |
| Solid tumours (NBL, WT, PNET) | 6 | 7 |
| Chronic myeloid leukaemia (CML) | 1 | 1 |
| Hodgkin lymphoma (HL) | 2 | 2 |
| Non-Hodgkin lymphoma (NHL) | 1 | 1 |
| Myelodysplastic syndrome (MDS) | 3 | 3 |
| Xanthogranuloma juvenile | 1 | 1 |
| Non malignant (NM) | 22 | 26 |
| Severe aplastic anaemia (SAA) | 4 | 5 |
| Metabolic diseases (WM) | 1 | 1 |
| Immune deficiencies (ID*) | 17 | 20 |
| Conditionning | ||
| Myeloablative (MA) | 50 | 58 |
| Reduced-intensity conditioning (RIC) | 24 | 28 |
| Non-myeloablative (NMA) | 8 | 10 |
| None | 4 | 4 |
| Graft versus host disease (GvHD) prophylaxis | ||
| ATG | 50 | 58 |
| CAMPATH | 13 | 15 |
| None | 22 | 26 |
| ATG and CAMPATH | 1 | 1 |
HLA ID SIB – HLA identical sibling; MUD – matched unrelated donor; HLA MM REL – HLA mismatched related donor; NBL – neuroblastoma; WT – Wilms tumour; PNET – primitive neuroectodermal tumour